Special Issue

COVID-19 Vaccines: From Immune Escape to Neutralizing Antibody-Based Therapeutics to Sterilizing Immunity

Message from the Guest Editor

The COVID-19 pandemic has been largely contained thanks to massive deployment of anti-spike vaccines. Different technologies have been in place, but none of them has been convincingly able to induce sterilizing mucosal immunity. Transmission of infection from vaccines to nonresponding immunosuppressed patients at risk for severe COVID-19 demands the development of next-generation mucosal vaccines able to induce sterilizing immunity. Mucosal vaccines come with additional benefits, such as oral route, home self-administration, and no need for needles or refrigeration chains. These manufacturing efforts are nevertheless halted by the ongoing evolution of the spike protein. Clinical experiences with neutralizing antibody-based therapeutics (i.e., anti-RBD monoclonal antibodies and convalescent plasma) have largely contributed to identifying the critical residues within the spike proteins which should be monitored for vaccine resistance.

Guest Editor

Dr. Fabrizio Maggi

1. Department of Medicine and Surgery, University of Insubria, Varese, Italy
2. Laboratory of Virology, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

Deadline for manuscript submissions

closed (25 July 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/100417

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI